BioArctic AB (publ) BRCTF
Set alert
At close · Oct 29
- YTD
- -15.37%
- 1 year
- -8.58%
- Open
- 35.00
- Prev close
- 29.40
- Mkt cap
- 2.61B
- Vol
- 250
- Avg vol
- 17
- EPS
- 0.13
- P/E
- 226.15
More statistics
- Low
- 35.00
- High
- 35.00
- Earnings
- Aug 26, 2026
News
1 day ago prnewswire.com
BioArctic's Nomination Committee appointed
STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The…
2 months ago prnewswire.com
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to…
2 months ago seekingalpha.com
BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript
BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript
2 months ago prnewswire.com
BioArctic and Mesenkia enter oncology research collaboration
STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement…
2 months ago prnewswire.com
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST
STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026, at 8:00…
3 months ago prnewswire.com
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER)…
4 months ago prnewswire.com
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and…
5 months ago prnewswire.com
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants…
5 months ago prnewswire.com
Bulletin from the Annual General Meeting in BioArctic AB (publ)
STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of…
5 months ago seekingalpha.com
BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
5 months ago prnewswire.com
BioArctic Interim Report for the period January - March 2026
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted…
5 months ago prnewswire.com
Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00…
8 months ago prnewswire.com
Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to…
8 months ago seekingalpha.com
BioArctic AB (publ) (BRCTF) Q4 2025 Earnings Call Transcript
BioArctic AB (publ) (BRCTF) Q4 2025 Earnings Call Transcript
8 months ago prnewswire.com
BioArctic Interim Report for the period October - December 2025
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai…
8 months ago prnewswire.com
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
STOCKHOLM, Feb. 11, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's fourth quarter report for October - December 2025 on Wednesday, February 18, 2026,…
10 months ago prnewswire.com
Leqembi included in China's commercial insurance innovative drug list
STOCKHOLM , Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance…
11 months ago prnewswire.com
New data on lecanemab to be presented at CTAD conference
STOCKHOLM , Nov. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's…
11 months ago prnewswire.com
Leqembi® approved for IV maintenance treatment in the United Kingdom
STOCKHOLM , Nov. 13, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks…
11 months ago seekingalpha.com
BioArctic AB (publ) (BRCTF) Q3 2025 Earnings Call Transcript
BioArctic AB (publ) (OTCPK:BRCTF) Q3 2025 Earnings Call November 13, 2025 3:30 AM EST Company Participants Gunilla Osswald - President & CEO Johanna Fälting - Chief R&D Officer and Head of Research &…